Did You Know? The Importance of HRD Testing in Advanced Ovarian Cancer With Maurie Markman, MD скачать в хорошем качестве

Did You Know? The Importance of HRD Testing in Advanced Ovarian Cancer With Maurie Markman, MD

Dr Maurie Markman discusses the importance of HRD testing in advanced ovarian cancer, using the Myriad MyChoice® companion diagnostic, to help identify patients who may be eligible for LYNPARZA® (olaparib) + bevacizumab for first-line maintenance therapy. Learn more: https://bit.ly/3xwKEMP In this video, Dr Maurie Markman, a medical oncologist, reviews homologous recombination deficiency (HRD) in advanced ovarian cancer, how HRD is tested, and the importance of testing for HRD in newly diagnosed advanced ovarian cancer to help inform treatment decisions and identify patients eligible for targeted treatment options. Important Product Information LYNPARZA is indicated in combination with bevacizumab as maintenance therapy for women with HRD+* advanced ovarian cancer after response to first-line platinum-based chemotherapy. *Select patients for this indication based on an FDA-approved companion diagnostic LYNPARZA is associated with serious and potentially fatal adverse events including Myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), pneumonitis, and venous thromboembolism (VTE). Monitor patients for signs and symptoms and discontinue LYNPARZA if MDS/AML or pneumonitis is confirmed. Monitor patients for signs and symptoms of VTE and treat as medically appropriate. LYNPARZA can cause fetal harm. Please see complete Prescribing Information, including Medication Guide, at https://bit.ly/LYNhcpPI. Please see the Important Safety Information within the video and at https://bit.ly/3xwKEMP. You may report side effects related to AstraZeneca products at https://us-aereporting.astrazeneca.co....